Literature DB >> 19072981

Characterization of a subpopulation of colon cancer cells with stem cell-like properties.

Peter Chu1, Dana J Clanton, Tracey S Snipas, Julia Lee, Eric Mitchell, Mai-Lan Nguyen, Eric Hare, Robert J Peach.   

Abstract

The biology of the normal colonic mucosa suggests that colon cancer originates from normal colon stem cells. CD44 cancer stem cells have been identified in breast and prostate cancer, and we therefore examined whether CD44 similarly identified colon cancer stem cells. Initial assays found CD44(hi) colon tumor cells to have enhanced soft agar colony-forming ability. Subsequently, CD44(hi) cells isolated from 4 primary colon adenocarcinoma xenografts were found to be highly tumorigenic in immune deficient mice. CD44(hi) cells consistently formed tumors with 1,000 cells, and in multiple experiments, as few as 10 and 100 CD44(hi) cells formed tumors in 7/10 and 21/28 mice, respectively. In contrast, CD44(-) colon tumor cells were either nontumorigenic or 10-50-fold less tumorigenic. CD44(hi) cells could be serially passaged up to 4 times in vivo, suggesting self-renewal capacity, and formed tumors that recapitulated the heterogeneity of the original patient tumor. CD44(hi) cells were significantly enriched for nuclear activated beta-catenin, a key element in normal stem/progenitor cells and in early colon tumor progression. Bromodeoxyuridine (BrdU) labeling studies indicated that CD44(hi) cells divide slowly relative to the CD44(-) cells, suggesting their tumorigenicity is not simply due to faster proliferation. Aldehyde dehydrogenase (ALDH) sort further increased the tumorigenicity of CD44(hi) cells from 2/2 patient tumors, but CD133 tumor cells in our hands did not have increased tumorigenicity. Our observations indicate that CD44 is a marker of stem-like cells in colon cancer, and support the use of additional markers to further purify colon cancer stem cells.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19072981     DOI: 10.1002/ijc.24061

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  77 in total

Review 1.  Prostate cancer stem cell biology.

Authors:  C Yu; Z Yao; Y Jiang; E T Keller
Journal:  Minerva Urol Nefrol       Date:  2012-03       Impact factor: 3.720

Review 2.  EGFR(S) inhibitors in the treatment of gastro-intestinal cancers: what's new?

Authors:  Shailender Singh Kanwar; Jyoti Nautiyal; Adhip P N Majumdar
Journal:  Curr Drug Targets       Date:  2010-06       Impact factor: 3.465

3.  Expression of CD176 (Thomsen-Friedenreich antigen) on lung, breast and liver cancer-initiating cells.

Authors:  Wei-Ming Lin; Uwe Karsten; Steffen Goletz; Ruo-Chuan Cheng; Yi Cao
Journal:  Int J Exp Pathol       Date:  2010-11-11       Impact factor: 1.925

4.  Complex display of putative tumor stem cell markers in the NCI60 tumor cell line panel.

Authors:  Christina H Stuelten; Susan D Mertins; Johanna I Busch; Meghan Gowens; Dominic A Scudiero; Mark W Burkett; Karen M Hite; Mike Alley; Melinda Hollingshead; Robert H Shoemaker; John E Niederhuber
Journal:  Stem Cells       Date:  2010-04       Impact factor: 6.277

5.  Highly enriched CD133(+)CD44(+) stem-like cells with CD133(+)CD44(high) metastatic subset in HCT116 colon cancer cells.

Authors:  Ke-li Chen; Feng Pan; Heng Jiang; Jian-fang Chen; Li Pei; Fang-wei Xie; Hou-jie Liang
Journal:  Clin Exp Metastasis       Date:  2011-07-13       Impact factor: 5.150

Review 6.  Colorectal cancer: genetic abnormalities, tumor progression, tumor heterogeneity, clonal evolution and tumor-initiating cells.

Authors:  Ugo Testa; Elvira Pelosi; Germana Castelli
Journal:  Med Sci (Basel)       Date:  2018-04-13

7.  An epigenetic switch involving NF-kappaB, Lin28, Let-7 MicroRNA, and IL6 links inflammation to cell transformation.

Authors:  Dimitrios Iliopoulos; Heather A Hirsch; Kevin Struhl
Journal:  Cell       Date:  2009-10-29       Impact factor: 41.582

8.  CD133 expression is not selective for tumor-initiating or radioresistant cell populations in the CRC cell line HCT-116.

Authors:  Claudia Dittfeld; Antje Dietrich; Susann Peickert; Sandra Hering; Michael Baumann; Marian Grade; Thomas Ried; Leoni A Kunz-Schughart
Journal:  Radiother Oncol       Date:  2010-03       Impact factor: 6.280

9.  In situ protein expression in tumour spheres: development of an immunostaining protocol for confocal microscopy.

Authors:  Louis-Bastien Weiswald; Jean-Marc Guinebretière; Sophie Richon; Dominique Bellet; Bruno Saubaméa; Virginie Dangles-Marie
Journal:  BMC Cancer       Date:  2010-03-22       Impact factor: 4.430

10.  Higher percentage of CD133+ cells is associated with poor prognosis in colon carcinoma patients with stage IIIB.

Authors:  Chun-Yan Li; Bao-Xiu Li; Yi Liang; Rui-Qing Peng; Ya Ding; Da-Zhi Xu; Xin Zhang; Zhi-Zhong Pan; De-Sen Wan; Yi-Xin Zeng; Xiao-Feng Zhu; Xiao-Shi Zhang
Journal:  J Transl Med       Date:  2009-07-07       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.